Yahoo Finance

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
Yahoo Finance

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering

Recursion Pharmaceuticals saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a significant follow-on ...

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
Investing

KeyBanc maintains $12 target on Recursion Pharmaceuticals post-acquisition

KeyBanc Capital Markets maintained its Overweight rating for Recursion following the FDA approval. In addition, Recursion announced a $30 million deal with Genentech and plans for a $200 million ...
manilatimes

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds ...
manilatimes

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to combine Recursion's end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of ...